CardioTech/Gish
This article was originally published in The Gray Sheet
Executive Summary
CardioTech will use Gish clean room facilities to manufacture polyurethane coronary artery bypass grafts after acquiring the Rancho Santa Margarita, California heart surgery products company for about $7.3 mil. in stock on Oct. 30. The deal also will increase CardioTech revenues by over 500%. CardioTech reported revenue of $3.2 mil. for the year ended March 31, while Gish had sales of $16 mil. in 2001...
You may also be interested in...
CardioTech Refocuses On Core Polymer Technologies After Gish Divestiture
CardioTech International is building its business around its polymer science and engineering expertise, following the recent divestiture of the Gish Biomedical disposable surgical product unit
CardioTech/Gish Introduces Downsized On-Pump Bypass System
CardioTech's Gish Biomedical subsidiary will launch its anticoagulant-coated, "on-pump" cardiac bypass system in July following 510(k) clearance of the system's six components, announced June 18
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.